Abstract
Lung cancer remains the leading cause of cancer-related death worldwide. The disease is classified into two major subtypes, small-cell lung cancer (SCLC) and the more prevalent non-small-cell lung cancer (NSCLC). First-line conventional therapies, such as chemotherapy, radiotherapy and surgery, have offered limited benefit, and patient prognosis remains poor with post-treatment recurrences representing a major cause of morbidity. Consequently, there is an urgent need for improved therapeutic options. Historically, NSCLC has been considered a non-immunogenic disease. However, increased understanding of tumor-immune interactions has challenged this paradigm in both lung and other malignancies, with cancer elimination by tumor-specific T cells increasingly well described in a myriad of solid tumors. Recent evidence has demonstrated that absent or weak anticancer responses are likely a product of tumor-derived immunosuppression. This knowledge, along with a greater appreciation for the role of T cells in lung cancer elimination, has driven development of novel immunotherapeutic approaches which are demonstrating remarkable clinical efficacy. This review examines the role of T cells in lung cancer, discussing the direction and clinical significance of current and future immunotherapeutic strategies.